

Plasma soluble vascular endothelial growth factor receptor  
prior to the clinical diagnosis of pre-eclampsia

Journal of Maternal-Fetal and Neonatal Medicine

17, 3-18

DOI: 10.1080/14767050400028816

Citation Report

#	ARTICLE	IF	CITATIONS
1	Screening for hypertensive disorders of pregnancy. , 0, , 45-62.		1
3	An elevated maternal plasma, but not amniotic fluid, soluble fms-like tyrosine kinase-1 (sFlt-1) at the time of mid-trimester genetic amniocentesis is a risk factor for preeclampsia. American Journal of Obstetrics and Gynecology, 2005, 193, 984-989.	0.7	87
4	Evidence supporting that the excess of the sVEGFR-1 concentration in maternal plasma in preeclampsia has a uterine origin. Journal of Maternal-Fetal and Neonatal Medicine, 2005, 18, 9-16.	0.7	99
5	Circulating Angiogenic Factors in the Pathogenesis and Prediction of Preeclampsia. Hypertension, 2005, 46, 1077-1085.	1.3	342
6	A role of the anti-angiogenic factor sVEGFR-1 in the "mirror syndrome" (Ballantyne's syndrome). Journal of Maternal-Fetal and Neonatal Medicine, 2006, 19, 607-613.	0.7	88
7	New Insights into the Biology of Preeclampsia. Biology of Reproduction, 2006, 74, 772-776.	1.2	43
8	Soluble Endoglin and Other Circulating Antiangiogenic Factors in Preeclampsia. New England Journal of Medicine, 2006, 355, 992-1005.	13.9	1,666
9	Late Postpartum Eclampsia: Examples and Review. Obstetrical and Gynecological Survey, 2006, 61, 471-480.	0.2	41
10	Circulating Angiogenic Factors and Placental Abruption. Obstetrics and Gynecology, 2006, 108, 338-344.	1.2	90
11	Quantitative distribution of a panel of circulating mRNA in preeclampsia versus controls. Prenatal Diagnosis, 2006, 26, 1115-1120.	1.1	47
12	Soluble endoglin contributes to the pathogenesis of preeclampsia. Nature Medicine, 2006, 12, 642-649.	15.2	1,653
13	Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. American Journal of Obstetrics and Gynecology, 2006, 194, 1034-1041.	0.7	101
14	Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. American Journal of Obstetrics and Gynecology, 2006, 195, 201-207.	0.7	212
15	Maternal serum concentration of soluble fms-like tyrosine kinase 1 and vascular endothelial growth factor in women with abnormal uterine artery Doppler and in those with fetal growth restriction. American Journal of Obstetrics and Gynecology, 2006, 195, 1668-1673.	0.7	88
16	Angiotensin Receptors, Autoimmunity, and Preeclampsia. Journal of Immunology, 2007, 179, 3391-3395.	0.4	54
17	Angiogenic proteins as markers for predicting preeclampsia. Expert Review of Obstetrics and Gynecology, 2007, 2, 61-65.	0.4	6
18	Sequential Changes in Antiangiogenic Factors in Early Pregnancy and Risk of Developing Preeclampsia. Hypertension, 2007, 50, 137-142.	1.3	271
19	Angiogenic factors in preeclampsia: so complex, so simple?. Nephrology Dialysis Transplantation, 2007, 22, 2753-2756.	0.4	11

#	ARTICLE	IF	CITATIONS
20	Placental Growth Factor and Soluble FMS-Like Tyrosine Kinase-1 in Early-Onset and Late-Onset Preeclampsia. <i>Obstetrics and Gynecology</i> , 2007, 109, 1368-1374.	1.2	172
21	Placental ischemia and soluble fms-like tyrosine kinase 1: Cause or consequence of preeclampsia?. <i>Kidney International</i> , 2007, 71, 959-961.	2.6	67
22	Alterations in Placental Growth Factor Levels before and after the Onset of Preeclampsia Are More Pronounced in Women with Early Onset Severe Preeclampsia. <i>Hypertension Research</i> , 2007, 30, 151-159.	1.5	78
23	Negative Regulation of Soluble Flt-1 and Soluble Endoglin Release by Heme Oxygenase-1. <i>Circulation</i> , 2007, 115, 1789-1797.	1.6	383
24	Potential Roles of Angiotensin Receptor-Activating Autoantibody in the Pathophysiology of Preeclampsia. <i>Hypertension</i> , 2007, 50, 269-275.	1.3	79
26	Mapping the Theories of Preeclampsia and the Role of Angiogenic Factors. <i>Obstetrics and Gynecology</i> , 2007, 109, 168-180.	1.2	155
27	The gonadotropins: Tissue-specific angiogenic factors?. <i>Molecular and Cellular Endocrinology</i> , 2007, 269, 65-80.	1.6	67
28	Thrombin Regulates Soluble fms-Like Tyrosine Kinase-1 (sFlt-1) Expression in First Trimester Decidua. <i>American Journal of Pathology</i> , 2007, 170, 1398-1405.	1.9	53
29	Elevated Serum sFlt-1/Ang-2 Ratio in Women with Preeclampsia. <i>Nephron Clinical Practice</i> , 2007, 106, c43-c50.	2.3	29
30	Placental growth hormone is increased in the maternal and fetal serum of patients with preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2007, 20, 651-659.	0.7	45
31	Maternal serum soluble CD30 is increased in normal pregnancy, but decreased in preeclampsia and small for gestational age pregnancies. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2007, 20, 867-878.	0.7	34
32	Performance of a panel of maternal serum markers in predicting preeclampsia at 11â€“15 weeks' gestation. <i>Prenatal Diagnosis</i> , 2007, 27, 1005-1010.	1.1	43
33	The timed-pregnant baboon animal model can be used for determining the role of soluble vascular endothelial growth factor receptors 1 and 2 during development. <i>Journal of Medical Primatology</i> , 2007, 36, 370-374.	0.3	6
34	Angiogenic factors and natural killer (NK) cells in the pathogenesis of preeclampsia. <i>Journal of Reproductive Immunology</i> , 2007, 76, 23-29.	0.8	58
35	Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 196, 239.e1-239.e6.	0.7	173
36	Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 196, 326.e1-326.e13.	0.7	215
37	60: Twin-to-twin transfusion syndrome: An anti-angiogenic state. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 197, S27.	0.7	0
38	Circulating soluble endoglin and placental abruption. <i>Prenatal Diagnosis</i> , 2008, 28, 852-858.	1.1	41

#	ARTICLE	IF	CITATIONS
39	Predictive value of angiogenic factors and uterine artery Doppler for early versus late onset pre-eclampsia and intrauterine growth restriction. <i>Ultrasound in Obstetrics and Gynecology</i> , 2008, 31, 303-309.	0.9	236
40	Soluble and membranous vascular endothelial growth factor receptor-1 in pregnancies complicated by pre-eclampsia. <i>Annals of Anatomy</i> , 2008, 190, 477-489.	1.0	39
41	Circulating angiogenic factors in singleton vs multiple-gestation pregnancies. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 198, 200.e1-200.e7.	0.7	40
42	Angiogenesis gene expression in mouse uterus during the common pathway of parturition. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 198, 539.e1-539.e8.	0.7	16
43	First-trimester maternal serum PP13 in the risk assessment for preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 199, 122.e1-122.e11.	0.7	129
44	Twin-to-twin transfusion syndrome: an antiangiogenic state?. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 198, 382.e1-382.e8.	0.7	51
45	Molecular mechanisms of preeclampsia. <i>Microvascular Research</i> , 2008, 75, 1-8.	1.1	252
46	Preeclampsia-Related Inflammatory Cytokines Regulate Interleukin-6 Expression in Human Decidual Cells. <i>American Journal of Pathology</i> , 2008, 172, 1571-1579.	1.9	133
47	The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2008, 21, 25-40.	0.7	100
48	Severe preeclampsia is characterized by increased placental expression of galectin-1. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2008, 21, 429-442.	0.7	65
49	Tissue factor and its natural inhibitor in pre-eclampsia and SGA. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2008, 21, 855-869.	0.7	54
50	Circulating Platelet-derived and Placenta-derived Microparticles Expose Flt-1 in Preeclampsia. <i>Reproductive Sciences</i> , 2008, 15, 1002-1010.	1.1	35
51	A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin) Tj ETQqO O O rgBT /Overlock 10 Tf 50 destined to develop preeclampsia and deliver a small for gestational age neonate. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2008, 21, 9-23.	0.7	592
52	The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2008, 21, 279-287.	0.7	264
53	Renal Physiology and Disease in Pregnancy. , 2008, , 2339-2398.		11
54	Alteration of Serum Soluble Endoglin Levels after the Onset of Preeclampsia Is More Pronounced in Women with Early-Onset. <i>Hypertension Research</i> , 2008, 31, 1541-1548.	1.5	42
55	Autoantibody From Women With Preeclampsia Induces Soluble Fms-Like Tyrosine Kinase-1 Production via Angiotensin Type 1 Receptor and Calcineurin/Nuclear Factor of Activated T-Cells Signaling. <i>Hypertension</i> , 2008, 51, 1010-1019.	1.3	159
56	Vascular endothelial growth factor genotypes and haplotypes are associated with pre-eclampsia but not with gestational hypertension. <i>Molecular Human Reproduction</i> , 2008, 15, 115-120.	1.3	54

#	ARTICLE	IF	CITATIONS
57	The role of an "anti-angiogenic state"™ in complications of pregnancy. Journal of Maternal-Fetal and Neonatal Medicine, 2008, 21, 3-7.	0.7	8
58	Preeclampsia and small-for-gestational age are associated with decreased concentrations of a factor involved in angiogenesis: Soluble Tie-2. Journal of Maternal-Fetal and Neonatal Medicine, 2008, 21, 389-402.	0.7	53
59	Low maternal concentrations of soluble vascular endothelial growth factor receptor-2 in preeclampsia and small for gestational age. Journal of Maternal-Fetal and Neonatal Medicine, 2008, 21, 41-52.	0.7	61
60	Maternal serum adiponectin multimers in preeclampsia. Journal of Perinatal Medicine, 2009, 37, 349-363.	0.6	60
61	Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model. Journal of Cellular and Molecular Medicine, 2010, 14, 1857-1867.	1.6	161
62	Circulating angiogenic factors in gestational proteinuria without hypertension. American Journal of Obstetrics and Gynecology, 2009, 200, 392.e1-392.e10.	0.7	40
63	The relationship of the level of circulating antiangiogenic factors to the clinical manifestations of preeclampsia. Prenatal Diagnosis, 2009, 29, 464-470.	1.1	66
64	Gene expression in chorionic villous samples at 11 weeks of gestation in women who develop preeclampsia later in pregnancy: implications for screening. Prenatal Diagnosis, 2009, 29, 1038-1044.	1.1	24
65	Early onset preeclampsia and second trimester serum markers. Prenatal Diagnosis, 2009, 29, 1109-1117.	1.1	14
66	ORIGINAL ARTICLE: Multiple Cytokine Profile in Plasma and Amniotic Fluid in a Mouse Model of Preterm Labor. American Journal of Reproductive Immunology, 2009, 62, 339-347.	1.2	15
67	Potential markers of preeclampsia – a review. Reproductive Biology and Endocrinology, 2009, 7, 70.	1.4	226
68	Preeclampsia. , 2009, , 341-357.		0
69	Tests to Predict Preeclampsia. , 2009, , 189-211.		3
70	Angiogenesis and Preeclampsia. , 2009, , 87-103.		3
71	Increased plasma soluble fms-like tyrosine kinase 1 and endoglin levels in pregnancies complicated with preeclampsia. Journal of Maternal-Fetal and Neonatal Medicine, 2009, 22, 565-570.	0.7	15
72	A subset of patients destined to develop spontaneous preterm labor has an abnormal angiogenic/anti-angiogenic profile in maternal plasma: Evidence in support of pathophysiologic heterogeneity of preterm labor derived from a longitudinal study. Journal of Maternal-Fetal and Neonatal Medicine. 2009. 22. 1122-1139.	0.7	71
73	A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. Journal of Maternal-Fetal and Neonatal Medicine, 2009, 22, 1021-1038.	0.7	254
74	Plasma soluble endoglin concentration in preeclampsia is associated with an increased impedance to flow in the maternal and fetal circulations. Ultrasound in Obstetrics and Gynecology, 2010, 35, 155-162.	0.9	50

#	ARTICLE	IF	CITATIONS
75	An automated method for the determination of the sFlt-1/PlGF ratio in the assessment of preeclampsia. American Journal of Obstetrics and Gynecology, 2010, 202, 161.e1-161.e11.	0.7	342
76	Angiogenic imbalances: the obstetric perspective. American Journal of Obstetrics and Gynecology, 2010, 203, 17.e1-17.e8.	0.7	38
77	Nicotine restores endothelial dysfunction caused by excess sFlt1 and sEng in an in vitro model of preeclamptic vascular endothelium: a possible therapeutic role of nicotinic acetylcholine receptor (nAChR) agonists for preeclampsia. American Journal of Obstetrics and Gynecology, 2010, 202, 464.e1-464.e6.	0.7	34
78	A decrease in maternal plasma concentrations of sVEGFR-2 precedes the clinical diagnosis of preeclampsia. American Journal of Obstetrics and Gynecology, 2010, 202, 550.e1-550.e10.	0.7	26
79	Pre-eclampsia: fitting together the placental, immune and cardiovascular pieces. Journal of Pathology, 2010, 221, 363-378.	2.1	177
80	Placental bed disorders in the genesis of the great obstetrical syndromes. , 2010, , 271-289.		10
82	Angiogenic factors and preeclampsia. , 0, , 229-242.		1
84	Alterations of Serum and Placental Endoglin in Pre-Eclampsia. Journal of International Medical Research, 2010, 38, 43-51.	0.4	5
85	Microbial invasion of the amniotic cavity in preeclampsia as assessed by cultivation and sequence-based methods. Journal of Perinatal Medicine, 2010, 38, 503-13.	0.6	74
86	Retinol binding protein 4 "a novel association with early-onset preeclampsia. Journal of Perinatal Medicine, 2010, 38, 129-39.	0.6	52
87	Maternal and neonatal circulating visfatin concentrations in patients with pre-eclampsia and a small-for-gestational age neonate. Journal of Maternal-Fetal and Neonatal Medicine, 2010, 23, 1119-1128.	0.7	30
88	Prospective Study of Placental Angiogenic Factors and Maternal Vascular Function Before and After Preeclampsia and Gestational Hypertension. Circulation, 2010, 122, 478-487.	1.6	299
89	The preeclampsia biomarkers soluble fms-like tyrosine kinase-1 and placental growth factor: current knowledge, clinical implications and future application. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2010, 151, 122-129.	0.5	58
90	Serum and plasma determination of angiogenic and anti-angiogenic factors yield different results: The need for standardization in clinical practice. Journal of Maternal-Fetal and Neonatal Medicine, 2010, 23, 820-827.	0.7	22
91	An imbalance between angiogenic and anti-angiogenic factors precedes fetal death in a subset of patients: results of a longitudinal study. Journal of Maternal-Fetal and Neonatal Medicine, 2010, 23, 1384-1399.	0.7	57
92	Could alterations in maternal plasma visfatin concentration participate in the phenotype definition of preeclampsia and SGA?. Journal of Maternal-Fetal and Neonatal Medicine, 2010, 23, 857-868.	0.7	35
93	Acute pyelonephritis during pregnancy changes the balance of angiogenic and anti-angiogenic factors in maternal plasma. Journal of Maternal-Fetal and Neonatal Medicine, 2010, 23, 167-178.	0.7	27
94	The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome. Journal of Maternal-Fetal and Neonatal Medicine, 2010, 23, 366-370.	0.7	50

#	ARTICLE	IF	CITATIONS
95	Evidence in support of a role for anti-angiogenic factors in preterm prelabor rupture of membranes. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2010, 23, 828-841.	0.7	27
96	Unexplained fetal death is associated with increased concentrations of anti-angiogenic factors in amniotic fluid. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2010, 23, 794-805.	0.7	22
97	Preeclampsia and pregnancies with small-for-gestational age neonates have different profiles of complement split products. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2010, 23, 646-657.	0.7	48
98	Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2011, 24, 1187-1207.	0.7	118
99	Preeclampsia, a Disease of the Maternal Endothelium. <i>Circulation</i> , 2011, 123, 2856-2869.	1.6	838
100	Preeclampsia and the anti-angiogenic state. <i>Pregnancy Hypertension</i> , 2011, 1, 17-21.	0.6	89
101	A Critical Review of Early-Onset and Late-Onset Preeclampsia. <i>Obstetrical and Gynecological Survey</i> , 2011, 66, 497-506.	0.2	397
102	Is inflammation the cause of pre-eclampsia?. <i>Biochemical Society Transactions</i> , 2011, 39, 1619-1627.	1.6	97
103	A longitudinal study of plasma levels of soluble fms-like tyrosine kinase 1 (sFlt1), placental growth factor (PlGF), sFlt1: PlGF ratio and vascular endothelial growth factor (VEGF-A) in normal pregnancy. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2011, 90, 1244-1251.	1.3	35
104	The "Great Obstetrical Syndromes" are associated with disorders of deep placentation. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 204, 193-201.	0.7	1,177
105	Circulating angiogenic and antiangiogenic factors in women with eclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 204, 152.e1-152.e9.	0.7	88
106	A guide towards pre-pregnancy management of defective implantation and placentation. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2011, 25, 367-387.	1.4	20
107	Pre-eclampsia: a maternal manifestation of a fetal adaptive response?. <i>Ultrasound in Obstetrics and Gynecology</i> , 2011, 38, 367-370.	0.9	11
108	Gadd45 $\beta$ as an upstream signaling molecule of p38 MAPK triggers oxidative stress-induced sFlt-1 and sEng upregulation in preeclampsia. <i>Cell and Tissue Research</i> , 2011, 344, 551-565.	1.5	51
109	Levels of soluble fms-like tyrosine kinase one in first trimester and outcomes of pregnancy: a systematic review. <i>Reproductive Biology and Endocrinology</i> , 2011, 9, 77.	1.4	29
110	Expression of Placental <i>FLT1</i> Transcript Variants Relates to Both Gestational Hypertensive Disease and Fetal Growth. <i>Hypertension</i> , 2011, 58, 70-76.	1.3	68
111	Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia. <i>Journal of Perinatal Medicine</i> , 2011, 39, 641-52.	0.6	228
112	Pilot Study of Extracorporeal Removal of Soluble Fms-Like Tyrosine Kinase 1 in Preeclampsia. <i>Circulation</i> , 2011, 124, 940-950.	1.6	311

#	ARTICLE	IF	CITATIONS
113	Biomarkers in Preeclampsia. , 2011, , 385-426.		3
114	Preeclampsia Due to Fetal Non-immune Hydrops: Mirror Syndrome and Review of Literature. Hypertension in Pregnancy, 2011, 30, 322-330.	0.5	39
115	Transcriptionally Active Syncytial Aggregates in the Maternal Circulation May Contribute to Circulating Soluble Fms-Like Tyrosine Kinase 1 in Preeclampsia. Hypertension, 2012, 59, 256-264.	1.3	148
116	Circulating anti-angiogenic factors during hypertensive pregnancy and increased risk of respiratory distress syndrome in preterm neonates. Journal of Maternal-Fetal and Neonatal Medicine, 2012, 25, 1447-1452.	0.7	34
117	Angiogenic Factors and the Risk of Adverse Outcomes in Women With Suspected Preeclampsia. Circulation, 2012, 125, 911-919.	1.6	526
118	Preeclampsia – Aetiology, Current Diagnostics and Clinical Management, New Therapy Options and Future Perspectives. Geburtshilfe Und Frauenheilkunde, 2012, 72, 1107-1116.	0.8	8
119	The Promise of Angiogenic Markers for the Early Diagnosis and Prediction of Preeclampsia. Clinical Chemistry, 2012, 58, 837-845.	1.5	108
120	Circulating Angiogenic Factors and Risk of Adverse Maternal and Perinatal Outcomes in Twin Pregnancies With Suspected Preeclampsia. Hypertension, 2012, 60, 451-458.	1.3	84
121	Magnesium sulfate therapy of preeclampsia: an old tool with new mechanism of action and prospect in management and prophylaxis. Hypertension Research, 2012, 35, 1005-1011.	1.5	11
122	A Comprehensive Review of Hypertension in Pregnancy. Journal of Pregnancy, 2012, 2012, 1-19.	1.1	173
123	Fulminant Postpartum Cerebral Vasoconstriction Syndrome. Archives of Neurology, 2012, 69, 111.	4.9	83
124	Renal Evaluation in Women with Preeclampsia. Nephron Extra, 2012, 2, 125-132.	1.1	19
126	Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion. Journal of Maternal-Fetal and Neonatal Medicine, 2012, 25, 498-507.	0.7	136
128	Recent biomarkers for the identification of patients at risk for preeclampsia: the role of uteroplacental ischemia. Expert Opinion on Medical Diagnostics, 2012, 6, 121-130.	1.6	19
129	Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of preeclampsia: a systematic review and meta-analysis. BJOG: an International Journal of Obstetrics and Gynaecology, 2012, 119, 778-787.	1.1	210
130	Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy. American Journal of Obstetrics and Gynecology, 2012, 207, 407.e1-407.e7.	0.7	116
131	The need to redefine preeclampsia. Expert Opinion on Medical Diagnostics, 2012, 6, 347-357.	1.6	6
132	Pré-eclâmpsia (indicador de doençã renal crônica): da gênese aos riscos futuros. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2012, 34, 87-93.	0.4	11



#	ARTICLE	IF	CITATIONS
134	Review: The feto-placental unit, pregnancy pathology and impact on long term maternal health. <i>Placenta</i> , 2012, 33, S37-S41.	0.7	64
135	Circulating Vascular Growth Factor (VEGF) Angiopoietin-1 (Angi-1) and Soluble Tie-2 Receptor in Pregnancy Complicated with Pre-eclampsia: A Prospective Study. <i>Journal of Obstetrics and Gynecology of India</i> , 2013, 63, 316-320.	0.3	7
136	Soluble VEGFR-1 in pathophysiology of pregnancies complicated by hypertensive disorders: the Indian scenario. <i>Journal of Human Hypertension</i> , 2013, 27, 107-114.	1.0	5
137	sFlt-1/PlGF ratio as a prognostic marker of adverse outcomes in women with early-onset preeclampsia. <i>Pregnancy Hypertension</i> , 2013, 3, 191-195.	0.6	19
138	Changes of placental syndecan-1 expression in preeclampsia and HELLP syndrome. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 463, 445-458.	1.4	42
139	<i>Chlamydia trachomatis</i> infection may increase the risk of preeclampsia. <i>Pregnancy Hypertension</i> , 2013, 3, 28-33.	0.6	19
140	Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2013, 208, 287.e1-287.e15.	0.7	122
141	Circulating Levels of Neutrophil Gelatinase-Associated Lipocalin (NGAL) Correlate With the Presence and Severity of Preeclampsia. <i>Reproductive Sciences</i> , 2013, 20, 1083-1089.	1.1	28
142	Maternal plasma concentrations of sST2 and angiogenic/anti-angiogenic factors in preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2013, 26, 1359-1370.	0.7	43
143	Perfusion with magnesium sulfate increases sFlt-1 secretion only in the fetal side of placenta of women with preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2013, 26, 116-122.	0.7	5
144	Placental trophoblast cell differentiation: Physiological regulation and pathological relevance to preeclampsia. <i>Molecular Aspects of Medicine</i> , 2013, 34, 981-1023.	2.7	306
145	Evidence of an imbalance of angiogenic/antiangiogenic factors in massive perivillous fibrin deposition (maternal floor infarction): a placental lesion associated with recurrent miscarriage and fetal death. <i>American Journal of Obstetrics and Gynecology</i> , 2013, 208, 310.e1-310.e11.	0.7	60
146	Placental angiogenin inhibitor (ribonuclease inhibitor), a novel gene in pre-eclampsia. <i>Pregnancy Hypertension</i> , 2013, 3, 39-43.	0.6	0
147	Renal Physiology and Disease in Pregnancy. , 2013, , 2689-2761.		19
148	The role and challenges of biomarkers in spontaneous preterm birth and preeclampsia. <i>Fertility and Sterility</i> , 2013, 99, 1117-1123.	0.5	36
149	New Developments in the Pathogenesis of Preeclampsia. <i>Advances in Chronic Kidney Disease</i> , 2013, 20, 265-270.	0.6	85
150	An Elevated Maternal Plasma Soluble fms-Like Tyrosine Kinase-1 to Placental Growth Factor Ratio at Midtrimester Is a Useful Predictor for Preeclampsia. <i>Obstetrics and Gynecology International</i> , 2013, 1-8.	0.5	36
151	Angiogenic factors in preeclampsia. <i>Current Opinion in Nephrology and Hypertension</i> , 2013, 22, 643-650.	1.0	27

#	ARTICLE	IF	CITATIONS
152	Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. <i>Hypertension in Pregnancy</i> , 2013, 32, 189-201.	0.5	130
153	Cost and resource implications with serum angiogenic factor estimation in the triage of pre-eclampsia. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2013, 120, 1224-1232.	1.1	41
154	Midtrimester amniotic fluid concentrations of angiogenic factors in relation to maternal, gestational and neonatal characteristics in normal pregnancies. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2013, 26, 75-78.	0.7	9
155	Automated measurement of sFlt1, PlGF and sFlt1/PlGF ratio in differential diagnosis of hypertensive pregnancy disorders. <i>Hypertension in Pregnancy</i> , 2013, 32, 459-473.	0.5	29
156	Maternal plasma soluble TRAIL is decreased in preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2014, 27, 217-227.	0.7	13
157	The therapeutic potential of antioxidants, ER chaperones, NO and H2S donors, and statins for treatment of preeclampsia. <i>Frontiers in Pharmacology</i> , 2014, 5, 119.	1.6	51
158	Placental Protein 13 (PP13) – A Placental Immunoregulatory Galectin Protecting Pregnancy. <i>Frontiers in Immunology</i> , 2014, 5, 348.	2.2	90
159	Evolutionary origins of the placental expression of chromosome 19 cluster galectins and their complex dysregulation in preeclampsia. <i>Placenta</i> , 2014, 35, 855-865.	0.7	92
160	Combination of plasma-soluble fms-like tyrosine kinase 1 and uterine artery Doppler for the prediction of preeclampsia in cases of elderly gravida. <i>Hypertension Research</i> , 2014, 37, 538-542.	1.5	29
161	Preeclampsia Is Associated with Lower Production of Vascular Endothelial Growth Factor by Peripheral Blood Mononuclear Cells. <i>Archives of Medical Research</i> , 2014, 45, 561-569.	1.5	13
162	Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2014, 27, 132-144.	0.7	68
163	A longitudinal study of circulating angiogenic and antiangiogenic factors and AT1-AA levels in preeclampsia. <i>Hypertension Research</i> , 2014, 37, 753-758.	1.5	62
164	Placental Pathology in Early-Onset and Late-Onset Fetal Growth Restriction. <i>Fetal Diagnosis and Therapy</i> , 2014, 36, 117-128.	0.6	234
165	ANGIOGENIC IMBALANCES IN THE PATHOGENESIS OF PREGNANCY COMPLICATIONS. <i>Fetal and Maternal Medicine Review</i> , 2014, 25, 42-58.	0.3	0
166	Statistical regression model of standard and new laboratory markers and its usefulness in prediction of preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2014, 27, 388-392.	0.7	6
167	Effects of sFlt-1 and alpha 2-macroglobulin on vascular endothelial growth factor-induced endothelin-1 upregulation in human microvascular endothelial cells. <i>Placenta</i> , 2014, 35, 64-69.	0.7	18
168	Prediction of Preeclampsia-Bench to Bedside. <i>Current Hypertension Reports</i> , 2014, 16, 491.	1.5	11
169	Angiogenic Factors in Diagnosis, Management, and Research in Preeclampsia. <i>Hypertension</i> , 2014, 63, 198-202.	1.3	106

#	ARTICLE	IF	CITATIONS
170	Pre-eclampsia part 1: current understanding of its pathophysiology. <i>Nature Reviews Nephrology</i> , 2014, 10, 466-480.	4.1	786
171	Pre-eclampsia part 2: prediction, prevention and management. <i>Nature Reviews Nephrology</i> , 2014, 10, 531-540.	4.1	125
172	Abnormal blood biomarkers in early pregnancy are associated with preeclampsia: a meta-analysis. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2014, 182, 194-201.	0.5	89
173	Urine proteomic studies in preeclampsia. <i>Proteomics - Clinical Applications</i> , 2015, 9, 501-506.	0.8	16
174	Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of preeclampsia in singleton pregnancy: implications for clinical practice. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015, 45, 241-246.	0.9	196
175	Full-Length Human Placental sFlt-1-e15a Isoform Induces Distinct Maternal Phenotypes of Preeclampsia in Mice. <i>PLoS ONE</i> , 2015, 10, e0119547.	1.1	50
176	Inflammatory biomarkers and spontaneous preterm birth among obese women. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2015, 29, 1-6.	0.7	10
177	Update on the Pathophysiological Implications and Clinical Role of Angiogenic Factors in Pregnancy. <i>Fetal Diagnosis and Therapy</i> , 2015, 37, 81-92.	0.6	59
178	Activation of Villous Trophoblastic p38 and ERK1/2 Signaling Pathways in Preterm Preeclampsia and HELLP Syndrome. <i>Pathology and Oncology Research</i> , 2015, 21, 659-668.	0.9	36
179	Antihypertensive therapy in preeclampsia is not modulated by VEGF polymorphisms. <i>Archives of Gynecology and Obstetrics</i> , 2015, 291, 799-803.	0.8	8
180	Serum biomarkers predictive of pre-eclampsia. <i>Biomarkers in Medicine</i> , 2015, 9, 563-575.	0.6	8
181	The role of microRNAs on angiogenesis and vascular pressure in preeclampsia: The evidence from systematic review. <i>Egyptian Journal of Medical Human Genetics</i> , 2015, 16, 313-325.	0.5	11
182	Potential targets for the treatment of preeclampsia. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 1517-1530.	1.5	29
183	Maternal plasma fetuin-A concentration is lower in patients who subsequently developed preterm preeclampsia than in uncomplicated pregnancy: a longitudinal study. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2015, 28, 1260-1269.	0.7	5
184	Ischemic placental syndrome – prediction and new disease monitoring. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2016, 29, 1-7.	0.7	8
185	Molecular Mechanisms of Preeclampsia. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a023473.	2.9	127
186	Evaluation of first trimester serum soluble endothelial cell-specific tyrosine kinase receptor in normal and affected pregnancies. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2015, 28, 1815-1821.	0.7	1
187	Tests to Predict Preeclampsia. , 2015, , 221-251.		3

#	ARTICLE	IF	CITATIONS
188	Screening for pre-eclampsia early in pregnancy: performance of a multivariable model combining clinical characteristics and biochemical markers. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2015, 122, 402-410.	1.1	34
189	Pre-eclampsia: its pathogenesis and pathophysiology. <i>Cardiovascular Journal of Africa</i> , 2016, 27, 71-78.	0.2	262
190	Soluble fms-like tyrosine kinase 1 promotes angiotensin II sensitivity in preeclampsia. <i>Journal of Clinical Investigation</i> , 2016, 126, 2561-2574.	3.9	111
191	KRYPTOR-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes. <i>Hypertension in Pregnancy</i> , 2016, 35, 330-345.	0.5	34
192	Vascular Growth Factors and Glomerular Disease. <i>Annual Review of Physiology</i> , 2016, 78, 437-461.	5.6	89
193	Angiogenic Factors in Preeclampsia. <i>Hypertension</i> , 2016, 67, 1072-1079.	1.3	121
194	Racial-ethnic differences in midtrimester maternal serum levels of angiogenic and antiangiogenic factors. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 359.e1-359.e9.	0.7	27
195	Strong inhibitory effect of pre-eclampsia serum on angiogenesis detected in vitro by human cell-based angiogenesis tests. <i>Pregnancy Hypertension</i> , 2016, 6, 367-373.	0.6	6
196	Gelsolin is an endogenous inhibitor of syncytiotrophoblast extracellular vesicle shedding in pregnancy. <i>Pregnancy Hypertension</i> , 2016, 6, 333-339.	0.6	9
197	Trophoblast mitochondrial function is impaired in preeclampsia and correlates negatively with the expression of soluble fms-like tyrosine kinase 1. <i>Pregnancy Hypertension</i> , 2016, 6, 313-319.	0.6	41
198	Maternal plasma angiogenic index-1 (placental growth factor/soluble vascular endothelial growth) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 underperfusion: a longitudinal case-cohort study. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, 629.e1-629.e17.	0.7	91
199	Association Between Hypertensive Disorders of Pregnancy and Later Risk of Cardiomyopathy. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1026.	3.8	106
200	Detection and confirmation of serum lipid biomarkers for preeclampsia using direct infusion mass spectrometry. <i>Journal of Lipid Research</i> , 2016, 57, 687-696.	2.0	48
201	The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2016, 29, 1214-1228.	0.7	63
202	Pravastatin to prevent recurrent fetal death in massive perivillous fibrin deposition of the placenta (MPFD). <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2016, 29, 855-862.	0.7	43
203	Myocardial performance index in hypertensive disorders of pregnancy: The relationship between blood pressures and angiogenic factors. <i>Hypertension in Pregnancy</i> , 2017, 36, 161-167.	0.5	13
204	Anti-angiogenesis and Preeclampsia in 2016. <i>Current Hypertension Reports</i> , 2017, 19, 6.	1.5	25
205	The maternal plasma proteome changes as a function of gestational age in normal pregnancy: a longitudinal study. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 67.e1-67.e21.	0.7	66

#	ARTICLE	IF	CITATIONS
206	Association Between Fetal Congenital Heart Defects and Maternal Risk of Hypertensive Disorders of Pregnancy in the Same Pregnancy and Across Pregnancies. <i>Circulation</i> , 2017, 136, 39-48.	1.6	73
207	Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 282-302.	0.7	183
208	Failure of physiologic transformation of spiral arteries, endothelial and trophoblast cell activation, and acute atherosclerosis in the basal plate of the placenta. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 216, 287.e1-287.e16.	0.7	111
209	Biomarkers in Preeclampsia. , 2017, , 555-594.		4
210	The prediction of fetal death with a simple maternal blood test at 24-28 weeks: a role for angiogenic index-1 (PlGF/sVEGFR-1 ratio). <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 682.e1-682.e13.	0.7	31
211	Angiogenic, Antiangiogenic Molecules, and Bioactive Lipids in Preeclampsia. <i>American Journal of Hypertension</i> , 2017, 30, 864-870.	1.0	3
212	Preeclampsia: Pathogenesis, Prevention, and Long-Term Complications. <i>Seminars in Nephrology</i> , 2017, 37, 386-397.	0.6	166
213	Microcirculatory blood flow derangements during severe preeclampsia and HELLP syndrome. <i>Pregnancy Hypertension</i> , 2017, 10, 124-130.	0.6	15
214	Human placental growth hormone in normal and abnormal fetal growth. <i>Biomedical Reports</i> , 2017, 7, 115-122.	0.9	39
215	Combination of copeptin, placental growth factor and total annexin V microparticles for prediction of preeclampsia at 10-14 weeks of gestation. <i>Placenta</i> , 2017, 58, 67-73.	0.7	25
216	Pathophysiology of preeclampsia: an angiogenic imbalance and long-lasting systemic vascular dysfunction. <i>Hypertension Research</i> , 2017, 40, 305-310.	1.5	92
217	Angiogenic imbalance as a contributor to the pathophysiology of preeclampsia among black African women. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2017, 30, 1335-1341.	0.7	15
218	Pathophysiology of Preeclampsia. , 2017, , 1724-1732.e2.		0
219	Early Detection of Preeclampsia Using Circulating Small non-coding RNA. <i>Scientific Reports</i> , 2018, 8, 3401.	1.6	46
220	sFlt-1/PLGF. <i>Comprehensive Gynecology and Obstetrics</i> , 2018, , 175-198.	0.0	0
221	Novel Therapies for Preeclampsia. <i>Comprehensive Gynecology and Obstetrics</i> , 2018, , 227-237.	0.0	0
222	Maternal plasma-soluble ST2 concentrations are elevated prior to the development of early and late onset preeclampsia – a longitudinal study. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2018, 31, 418-432.	0.7	26
223	Screening and prevention of preterm preeclampsia – A prime time to act. <i>Australasian Journal of Ultrasound in Medicine</i> , 2018, 21, 187-190.	0.3	1

#	ARTICLE	IF	CITATIONS
224	Association of antepartum blood pressure levels and angiogenic profile among women with chronic hypertension. <i>Pregnancy Hypertension</i> , 2018, 14, 110-114.	0.6	9
225	Cerebrospinal Fluid Protein Changes in Preeclampsia. <i>Hypertension</i> , 2018, 72, 219-226.	1.3	25
226	Angiogenic biomarkers in triage and risk for preeclampsia with severe features. <i>Pregnancy Hypertension</i> , 2018, 13, 100-106.	0.6	43
227	Clinical Presentation of Preeclampsia and the Diagnostic Value of Proteins and Their Methylation Products as Biomarkers in Pregnant Women with Preeclampsia and Their Newborns. <i>Journal of Pregnancy</i> , 2018, 2018, 1-23.	1.1	39
228	Circulating MicroRNAs and Bioactive Lipids in Pre-Eclampsia and Its Cardiovascular Sequelae. <i>American Journal of Hypertension</i> , 2018, 31, 1079-1086.	1.0	4
229	Long term follow up of biomarkers of podocyte damage and renal function in patients with and without preeclampsia. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2018, 40, 339-343.	0.4	3
230	Disruption in the Regulation of Immune Responses in the Placental Subtype of Preeclampsia. <i>Frontiers in Immunology</i> , 2018, 9, 1659.	2.2	70
231	Integrated Systems Biology Approach Identifies Novel Maternal and Placental Pathways of Preeclampsia. <i>Frontiers in Immunology</i> , 2018, 9, 1661.	2.2	146
232	Upregulation of Nrf2 and Decreased Redox Signaling Contribute to Renoprotective Effects of Chemerin Receptor Blockade in Diabetic Mice. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2454.	1.8	19
233	A Review of Angiogenic Imbalance in HIV-Infected Hypertensive Disorders of Pregnancy. <i>Current Hypertension Reports</i> , 2019, 21, 69.	1.5	5
234	Risk Factor and Biomarker of Preeclampsia. , 2019, , .		1
235	Circulating soluble fms-like tyrosine kinase-1, soluble endoglin and placental growth factor during pregnancy in normotensive women in KwaZulu-Natal, South Africa. <i>African Health Sciences</i> , 2019, 19, 1821.	0.3	2
236	Status of VEGF in preeclampsia and its effect on endoplasmic reticulum stress in placental trophoblast cells. <i>European Journal of Obstetrics and Gynecology and Reproductive Biology: X</i> , 2019, 4, 100070.	0.6	12
237	Abnormal expression and clinical significance of 25-hydroxyvitamin D and sFlt-1 in patients with preeclampsia. <i>Journal of International Medical Research</i> , 2019, 47, 4673-4682.	0.4	7
238	Midpregnancy testing for soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF): An inter-assay comparison of three automated immunoassay platforms. <i>Placenta</i> , 2019, 86, 11-14.	0.7	3
239	The diagnostic conundrum of maternal mirror syndrome progressing to pre-eclampsia – A case report. <i>Case Reports in Women's Health</i> , 2019, 23, e00122.	0.2	8
240	The prediction of early preeclampsia: Results from a longitudinal proteomics study. <i>PLoS ONE</i> , 2019, 14, e0217273.	1.1	81
241	The Role of Nitric Oxide, ADMA, and Homocysteine in The Etiopathogenesis of Preeclampsia – Review. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2757.	1.8	37

#	ARTICLE	IF	CITATIONS
242	Early onset preeclampsia in a model for human placental trophoblast. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 4336-4345.	3.3	55
243	Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nature Reviews Nephrology, 2019, 15, 275-289.	4.1	609
244	Anti-angiogenic isoform of vascular endothelial growth factor-A in cardiovascular and renal disease. Advances in Clinical Chemistry, 2019, 88, 1-33.	1.8	21
245	Accelerated growth of hemangioblastoma in pregnancy: the role of proangiogenic factors and upregulation of hypoxia-inducible factor (HIF) in a non-oxygen-dependent pathway. Neurosurgical Review, 2019, 42, 209-226.	1.2	14
246	The profiles of soluble adhesion molecules in the "great obstetrical syndromes". Journal of Maternal-Fetal and Neonatal Medicine, 2019, 32, 2113-2136.	0.7	32
247	ELABELA plasma concentrations are increased in women with late-onset preeclampsia. Journal of Maternal-Fetal and Neonatal Medicine, 2020, 33, 5-15.	0.7	37
248	Placental growth factor in suspected preterm preeclampsia: a review of the evidence and practicalities of implementation. BJOG: an International Journal of Obstetrics and Gynaecology, 2020, 127, 1590-1597.	1.1	17
249	Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders. American Journal of Obstetrics and Gynecology, 2022, 226, S1019-S1034.	0.7	120
250	Proteinuria during pregnancy: definition, pathophysiology, methodology, and clinical significance. American Journal of Obstetrics and Gynecology, 2022, 226, S819-S834.	0.7	46
251	Increased NDRG1 expression suppresses angiogenesis via PI3K/AKT pathway in human placental cells. Pregnancy Hypertension, 2020, 21, 106-110.	0.6	8
252	Regulation of Uterine Spiral Artery Remodeling: a Review. Reproductive Sciences, 2020, 27, 1932-1942.	1.1	47
253	Cytokine profiles in maternal serum are candidates for predicting an optimal timing for the delivery in early-onset fetal growth restriction. Prenatal Diagnosis, 2020, 40, 728-737.	1.1	2
254	Preeclampsia and HELLP syndrome, the role of the liver. Journal of Maternal-Fetal and Neonatal Medicine, 2021, 34, 117-123.	0.7	43
255	The Effect of Recombinant Vascular Endothelial Growth Factor (VEGF)-121 Towards Placenta Growth Factor Serum Levels in Female Mice (Mus Musculus) with Preeclampsia Model. Maternal and Child Health Journal, 2021, 6, 307-313.	0.0	0
256	Real life outpatient biomarker use in management of hypertensive pregnancies in third trimester in a low resource setting: ROBUST study. Pregnancy Hypertension, 2021, 23, 97-103.	0.6	9
257	Prediction of preeclampsia throughout gestation with maternal characteristics and biophysical and biochemical markers: a longitudinal study. American Journal of Obstetrics and Gynecology, 2022, 226, 126.e1-126.e22.	0.7	18
258	Maternal systemic vascular dysfunction in a primate model of defective uterine spiral artery remodeling. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 320, H1712-H1723.	1.5	8
259	Serum biomarkers for the prediction and diagnosis of preeclampsia: A meta-analysis. Journal of Taibah University Medical Sciences, 2022, 17, 14-27.	0.5	7

#	ARTICLE	IF	CITATIONS
260	HIV Associated Preeclampsia: A Multifactorial Appraisal. International Journal of Molecular Sciences, 2021, 22, 9157.	1.8	9
261	Maternal endothelial dysfunction in HIV-associated preeclampsia comorbid with COVID-19: a review. Hypertension Research, 2021, 44, 386-398.	1.5	14
262	Physiopathology. , 2019, , 41-64.		1
263	The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome. Journal of Maternal-Fetal and Neonatal Medicine, 2010, 23, 1-6.	0.7	26
264	Impact of Preeclampsia on Clinical and Functional Outcomes in Women With Peripartum Cardiomyopathy. Circulation: Heart Failure, 2017, 10, .	1.6	44
265	Serum Levels of Angiogenic Factors Distinguish Between Women with Preeclampsia and Normotensive Pregnant Women But Not Severity of Preeclampsia in an Obstetric Center in Turkey. Medical Science Monitor, 2019, 25, 6935-6942.	0.5	15
266	Recent advances in the diagnosis and management of pre-eclampsia. Faculty Reviews, 2020, 9, 10.	1.7	6
267	Plasma Concentrations of Soluble Endoglin versus Standard Evaluation in Patients with Suspected Preeclampsia. PLoS ONE, 2012, 7, e48259.	1.1	49
268	In Vivo Experiments Reveal the Good, the Bad and the Ugly Faces of sFlt-1 in Pregnancy. PLoS ONE, 2014, 9, e110867.	1.1	40
269	Systematic Review of Micro-RNA Expression in Pre-Eclampsia Identifies a Number of Common Pathways Associated with the Disease. PLoS ONE, 2016, 11, e0160808.	1.1	61
270	The prediction of late-onset preeclampsia: Results from a longitudinal proteomics study. PLoS ONE, 2017, 12, e0181468.	1.1	84
271	Placental cytokines and preeclampsia. Frontiers in Bioscience - Landmark, 2007, 12, 2706.	3.0	50
272	A Brief Overview of Preeclampsia. Journal of Clinical Medicine Research, 2013, 6, 1-7.	0.6	125
273	The effect of Silymarin on VEGF, VEGFR-1 and IL-1 $\beta$ levels in placental cultures of severe preeclamptic women. Journal of the Turkish German Gynecology Association, 2014, 15, 30-35.	0.2	2
274	Epigenetic processes during preeclampsia and effects on fetal development and chronic health. Clinical Science, 2021, 135, 2307-2327.	1.8	25
277	Postpartum Angiopathy and Related Disorders. , 2011, , 69-77.		0
279	Placenta related pathogenic factors for preeclampsia. Open Journal of Obstetrics and Gynecology, 2012, 02, 340-345.	0.1	1
280	Investigation of maternal plasma VEGF levels in early membrane rupture. The Journal of Kartal Training and Research Hospital, 0, , .	0.0	0



#	ARTICLE	IF	CITATIONS
282	Angiogenic factors in normal pregnancy and preeclampsia. <i>Obstetrica Si Ginecologie</i> , 2019, 2, 61.	0.0	0
284	Comparison of thyroid hormone levels between normal and preeclamptic pregnancies. <i>Medical Journal of the Islamic Republic of Iran</i> , 2014, 28, 1.	0.9	60
285	Resveratrol inhibits proteinase-activated receptor-2-induced release of soluble vascular endothelial growth factor receptor-1 from human endothelial cells. <i>EXCLI Journal</i> , 2013, 12, 598-604.	0.5	11
286	Angiogenesis and Preeclampsia. , 2022, , 165-185.		0
287	How Soluble Fms-Like Tyrosine Kinase 1 Could Contribute to Blood-Brain Barrier Dysfunction in Preeclampsia?. <i>Frontiers in Physiology</i> , 2021, 12, 805082.	1.3	5
288	Placental sFlt-1 Gene Delivery in Early Primate Pregnancy Suppresses Uterine Spiral Artery Remodeling. <i>Endocrinology</i> , 2022, 163, .	1.4	5
289	Everything Else. <i>Physician Assistant Clinics</i> , 2022, 7, 305-317.	0.1	0
290	sFlt-1/PlGF ratio for prediction of preeclampsia in clinical routine: A pragmatic real-world analysis of healthcare resource utilisation. <i>PLoS ONE</i> , 2022, 17, e0263443.	1.1	9
308	Long-term observational study of renal outcome after preeclampsia: Role of soluble fms-like tyrosine kinase-1 (sFlt-1)/ placental growth factor (PlGF) and endoglin. <i>Annals of Medicine and Surgery</i> , 2022, 78, 103818.	0.5	1
309	Immature Platelet Fraction and Thrombin Generation: Preeclampsia Biomarkers. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2022, 44, 771-775.	0.3	3
310	Serum MUC3 Protein as a Novel Marker of Gestational Hypertensive Disorders. <i>Journal of Obstetrics and Gynecology of India</i> , 0, , .	0.3	0
311	Toward a new taxonomy of obstetrical disease: improved performance of maternal blood biomarkers for the great obstetrical syndromes when classified according to placental pathology. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 227, 615.e1-615.e25.	0.7	24
312	Human Plasma Proteome During Normal Pregnancy. <i>Journal of Proteome Research</i> , 2022, 21, 2687-2702.	1.8	7
313	Placental growth fActor Repeat sampling for Reduction of adverse perinatal Outcomes in women with suspecTed pre-eclampsia: study protocol for a randomised controlled trial (PARROT-2). <i>Trials</i> , 2022, 23, .	0.7	4
314	Placental Therapeutic Targets and Nanodelivery Systems. <i>Molecular Pharmaceutics</i> , 2022, 19, 3730-3748.	2.3	1
315	Preeclampsia at term can be classified into 2 clusters with different clinical characteristics and outcomes based on angiogenic biomarkers in maternal blood. <i>American Journal of Obstetrics and Gynecology</i> , 2023, 228, 569.e1-569.e24.	0.7	12
316	Identification of vascular endothelial growth factor in preeclampsia in Iraqi women. <i>Journal of Medicine and Life</i> , 2022, 15, 1252-1256.	0.4	0
317	Soluble suppression of tumorigenicity-2 in pregnancy with a small-for-gestational-age fetus and with preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2023, 36, .	0.7	4

#	ARTICLE	IF	CITATIONS
318	One-third of patients with eclampsia at term do not have an abnormal angiogenic profile. <i>Journal of Perinatal Medicine</i> , 2022, .	0.6	1
319	Predictive and diagnostic value of serum sVEGFR-1 level in women with preeclampsia: A prospective controlled study. <i>TâşÅrk Jinekoloji Ve Obstetrik Dernei Dergisi</i> , 2022, 19, 268-274.	0.3	0
320	Similar Pro- and Antiangiogenic Profiles Close to Delivery in Different Clinical Presentations of Two Pregnancy Syndromes: Preeclampsia and Fetal Growth Restriction. <i>International Journal of Molecular Sciences</i> , 2023, 24, 972.	1.8	7
321	Accuracy of placental growth factor alone or in combination with soluble fms-like tyrosine kinase-1 or maternal factors in detecting preeclampsia in asymptomatic women in the second and third trimesters: a systematic review and meta-analysis. <i>American Journal of Obstetrics and Gynecology</i> , 2023, 229, 222-247.	0.7	6
322	Understanding the Role of Chemerin in the Pathophysiology of Pre-Eclampsia. <i>Antioxidants</i> , 2023, 12, 830.	2.2	2